Citadel Advisors
GCTK icon

Citadel Advisors’s GlucoTrack GCTK Stock Holding History

Citadel Advisors’s Portfolio GCTK Stock Details GCTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4
Closed -$7.27K – 14677
2024
Q1 		$7.27K Sell
4
-3
-43% -$4.71K ﹤0.01% 13623
2023
Q4 		$10.2K Buy
7
+2
+40% +$2.65K ﹤0.01% 13113
2023
Q3 		$8.34K Buy
+5
New +$8.98K ﹤0.01% 13195

Other funds holding GCTK

AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's GCTK Position: Q2 2024 in Review

Citadel Advisors sold out of GlucoTrack (GCTK) in Q2 2024, closing a stake of 4 shares — an estimated $7.27K sold.

Citadel Advisors first reported a position in GCTK in Q3 2023 and held it in 3 quarters. The position peaked at $10.2K in Q4 2023. 3 funds tracked by Wall St. Rank hold GCTK as of Q2 2024.

  • Citadel Advisors reported no remaining GlucoTrack position as of Q2 2024 after selling out during the quarter.
  • Citadel Advisors sold 4 GlucoTrack shares in Q2 2024, an estimated $7.27K.
  • Citadel Advisors first reported a position in GlucoTrack in Q3 2023 and held it in 3 quarters.
  • Citadel Advisors's GlucoTrack position peaked at $10.2K in Q4 2023.
  • 3 funds tracked by Wall St. Rank held GlucoTrack as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.